ATOMO DIAGNOSTICS LIMITED — Board/Management Information 2021

Sep 14, 2021

15 September 2021

==> picture [182 x 52] intentionally omitted <==

ASX Announcement

Appointment of Independent Non-Executive Director

Atomo Diagnostics Limited ( Atomo ) is pleased to welcome Ms Deborah Neff as an independent Non-Executive Director effective 15 September 2021.

Based in the US, Deborah is a veteran of the life sciences industry with experience in building market-leading global businesses and product commercialisation. Currently, she is advising several early-stage companies developing innovative technology to improve patient care. Most recently, she was the CEO of, Evanostics, LLC, a development stage company focused on systems for applications in point-of-care diagnostic testing in forensic and clinical toxicology. Prior to that, she was the Chief Operating Officer at Complete Genomics Inc., a life sciences company in whole genome and exome sequencing. Deborah continues as the principal of a privately held consulting company, DJN Consulting, LLC. that she formed in 2013.

Prior to Complete Genomics, Deborah served as the Chief Operating Officer of Pathwork Diagnostics, Inc. and previously as CEO of Predicant Biosciences Inc. Deborah served as the global president of BD Biosciences, a major business segment of Becton Dickinson and Company until 2003. Her work experience at BD Biosciences over 15 years included various management positions including general manager, vice president and director of several business areas.

Deborah’s work in life sciences has included the areas of cancer diagnostics, immunocytometry and genomics, having establishing a certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines.

Deborah served as a board member and executive management advisor for Galt Inc. and Vortex Biosciences Inc, and served on the board of BioRad, Inc. She is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation Inc., boards, which were acquired by Abbott Laboratories and Pall Corporation respectively.

Deborah is an Executive Trustee of the UC Davis Foundation Board and Chairs the Global Campaign Leadership Committee. She also chairs the College of Biological Sciences Dean’s Leadership Council at the University.

Deborah earned a B.S. in Physiology from UC Davis in 1976 and completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.

Commenting on the appointment, Atomo’s Chair John Keith said, “On behalf of the Board, I extend a warm welcome to Deborah. Deborah brings significant expertise in the life sciences industry including product commercialisation and we look forward to her valuable contribution.”

==> picture [182 x 52] intentionally omitted <==

In accordance with Atomo’s Constitution, Deborah will retire and seek re-election at Atomo’s 2021 Annual General Meeting, to be held on Thursday, 28 October 2021.

For more information, please contact:

Jane Lowe John Kelly IR Department Managing Director, Atomo jane.lowe@irdepartment.com.au john.kelly@atomodiagnostics.com Phone: +61 411 117 774 Phone: +61 401 922 279

This announcement was authorised by John Keith, Non-Executive Chair.

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. Atomo has supply agreements in place for tests targeting infectious diseases including COVID-19, HIV and viral vs bacterial differentiation.

See more at www.atomodiagnostics.com.